Clinical trials: Kidney Functional
Renal Impairment
Single-Dose PK Study of GBT440 in Subjects With Renal Impairment
A Phase 1, multiple center, nonrandomized, open-label, parallel group study of a single oral dose of GBT440 administered in subjects with mild, moderate, or severe renal impairment disease and healthy subjects with normal renal…
- Trial name
- NCT03161015
- Testing
- GBT440
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Global Blood Therapeutics
Type2Diabetes
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function
This study is a single-dose, parallel grouping, open-label phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of PB-119 in subjects with different degrees of renal insufficiency…
- Trial name
- NCT05328843
- Testing
- PB119
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PegBio Co., Ltd.
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally
Researchers are looking for a better way to treat people who have vasomotor symptoms (VMS). The symptoms of VMS are hot flashes. These symptoms can be caused by changes in sex hormone levels.
- Trial name
- NCT05071729
- Testing
- Elinzanetant (BAY3427080)
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Bayer
Renal Impairment
The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function.
This study is divided two parts into: Part A and Part B. Part A will recruit 24 research participants, and Part B will recruit 16 research participants.
- Trial name
- D2570-107 (NCT07715175)
- Testing
- D-2570
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Type 2 Diabetes Mellitus (T2DM), Renal Insuficiency
The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency
The trial was designed in a single dose, open, non-randomized, multi-dose parallel control group. The study of patients were mild and moderate renal insufficiency, and matched healthy subjects.
- Trial name
- RI (NCT06883656)
- Testing
- SAL067
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Renal Impairment
A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function
To characterize the pharmacokinetics of LCI699 following a single oral dose in adult subjects with various degrees of impaired renal function.
- Trial name
- NCT02399202
- Testing
- osilodrostat
- Where
- 2 sites in Bulgaria, Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Blood Pressure
The Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function
To determine the effect of (1) increased sodium intake and (2) increased potassium intake on blood pressure, vascular function and renal function in untreated (pre)hypertensive subjects.
- Conditions
- Hypertension, Blood Pressure, Vascular Function, Renal Function
- Trial name
- KaNa (NCT01575041)
- Testing
- Sodium, Potassium
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wageningen University
Nephropathy, Hypoxia
Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
Background: Inhibiting the sodium-glucose cotransporter-2 (SGLT2) has been observed to reduce risk of cardiovascular events and kidney failure in type 2 diabetes.
- Conditions
- Nephropathy, Hypoxia, Mitochondrial Alteration, Type 1 Diabetes
- Trial name
- Astronaut (NCT04193566)
- Testing
- Forxiga
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Cancer
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
This is a Phase Ib, open-label, multiple-center, multiple-dose study designed to evaluate the pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies (including hepatocellular carcinoma and…
- Trial name
- NCT01546519
- Testing
- Vismodegib
- Where
- 5 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Graft Failure, Dialysis
Factors for Impairment of Renal Graft Function in Intensive Care
hypothesis = hospitalization in the intensive care unit (ICU) has an impact on the outcome of the renal graft, due to the therapeutic and exploratory procedures performed.
- Conditions
- Graft Failure, Dialysis, Chronic Kidney Failure
- Trial name
- RENAGRAF (NCT06191146)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Severe Renal Impairment
A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine
The purpose of this study is to assess the effect of severe renal impairment on the steady-state PK, as well as safety and tolerability, of ranolazine, compared to subjects with normal renal function.
- Trial name
- NCT01675973
- Testing
- RANEXA
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Chronic Kidney Disease
Evaluation of New Markers to Assess Kidney Function
Glomerular filtration rate (GFR) is widely accepted as the best index of kidney function in health and disease, and accurate values are required for optimal clinical decision making and in large-scale epidemiologic studies and…
- Trial name
- NCT00938561
- Testing
- Inulin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Fabry Disease
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
This study will assess the safety, tolerability, and pharmacokinetics (PK) study of a single dose of 150 mg AT1001 (migalastat HCl, GR181413A) administered orally to healthy subjects with normal renal function and to subjects…
- Trial name
- NCT01730469
- Testing
- AT1001 150 mg
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Healthy Subjects
The Effect of Nicardipine on Kidney Function During Orthognathic Surgery Under Hypotensive Anesthesia
Since nicardipine is known to protect kidney function, nicardipine infusion will result in better renal parameters measured in this study.
- Trial name
- NCT01175746
- Testing
- Nicardipine, remifentanil
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Renal Impairment, Tuberculosis
Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
This is a Phase 1, open-label, single-dose, sequential group study to compare the safety and pharmacokinetics (PK) of pretomanid in the following groups of participants: 1) participants with severe renal impairment including…
- Trial name
- NCT03896750
- Testing
- PA-824
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Diseases, End Stage Renal Disease
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
The purpose of this study is to evaluate the effect of renal function on the biological activity of telavancin using blood samples obtained from subjects with normal renal function, severe renal impairment, and end stage renal…
- Trial name
- NCT01238796
- Testing
- telavancin
- Where
- 4 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Cumberland Pharmaceuticals
Hyperlipidemias
A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function
The primary objective of this study is to evaluate pharmacokinetics of HRS-1301 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal…
- Trial name
- NCT07322016
- Testing
- HRS-1301 Tablet
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Renal Impairment
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.
- Trial name
- NCT02508506
- Testing
- ALKS 5461
- Where
- 3 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Renal Impairment
An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment
Multi-center, non-randomized, open-label, single-dose, parallel group study to determine the effect of impaired renal function on the PK of deferiprone and its 3-O-glucuronide metabolite following a single oral dose of 33mg/kg…
- Trial name
- NCT01770652
- Testing
- Deferiprone
- Where
- 2 sites in Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- ApoPharma
COVID 19
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects without renal impairment, matched for age, body weight and, to the extent…
- Trial name
- NCT06698549
- Testing
- ALG-097558
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics